UrgoStart Border Logo

Newer addition to the range: discover UrgoStart Plus
 

Reduces healing time by 100 days on average (1)

 

Benefits

UrgoStart Border pack

  • UrgoStart is the only local treatment clinically proven to close more wounds and to reduce healing time (1-4)
  • UrgoStart significantly improves patients’ quality of life (2,3)
  • UrgoStart is cost effective (5)

 

Indications

UrgoStart is indicated for low to moderately exuding leg ulcers, diabetic foot ulcers, pressure ulcers and long-standing acute wounds. The UrgoStart heel version is recommended for the treatment of exuding wounds located in the heel area.

 

Precautions for use and Contra-Indications

  • In order not to delay any optimal treatment, UrgoStart Pad and Border are contraindicated in cancerous wounds and wounds which may reveal a deep abscess
  • Do not use when there is a known sensitivity to UrgoStart

Ordering codes

Product

Dressing Size

Pack size

Product code

PIP code

NPC code^

UrgoStart

6 x 6 cm

10

506472

347-1844

ELA417

10 x 10 cm

10

506473

347-1851

ELA418

15 x 20 cm

10

506474

347-1869

ELA626

12 x 19 cm (Heel format)

10

506475

347-1877

ELA420

Product

Dressing Size

Pack size

Product code

PIP code

NPC code^

UrgoStart Border

8 x 8 cm

10

552291

406-4390

ELZ879

10 x 10 cm

10

552292

406-4408

ELZ880

13 x 13 cm

10

552293

406-4416

ELZ881

15 x 20 cm

10

552296

406-4424

ELZ882

20 x 20 cm (sacrum)

5

552297

406-4887

ELZ883

^NPC = NHS Supply Chain ordering code

 

References:

(1) Münter KC, Meaume S, Augustin M, Senet P, Kérihuel J.C. The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings. J Wound Care. 2017 Feb; 26 (Sup2): S4-S15. Erratum in: J Wound Care. 2017 Mar 2; 26(3): 153

(2) Meaume S, Truchetet F, Cambazard F et al. A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-OligoSaccharide Factor wound dressing in the local management of venous leg ulcers. Wound Repair Regen. 2012; 20: 4, 500–511.

(3) Meaume S, Dompmartin A, Lazareth I, Sigal M, Truchetet F, Sauvadet A, Bohbot S. Quality of life in patients with leg ulcers: results from CHALLENGE, a double-blind randomized controlled trial. Journal of Wound Care. 2017; 26 (7): 368-379.

(4) Edmonds M, Lázaro-Martínez JL, Alfayate-García JM, Martini J, Petit JM, Rayman G, Lobmann R, Uccioli L, Sauvadet A, Bohbot S, Kerihuel JC, Piaggesi A. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol. 2018 Mar;6(3):186-196.

(5) An Economic Evaluation of UrgoStart® for Patients with Chronic Leg Ulcers in the United Kingdom. York University. Data on file. Urgo, 2011.